XML 46 R61.htm IDEA: XBRL DOCUMENT v3.20.1
License agreements - MorphoSys (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Mar. 03, 2020
Mar. 31, 2020
Jan. 31, 2020
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
[1]
Unrealized gain (loss) on long term investments       $ (48,132) $ 20,989  
Long term investments   $ 180,993   180,993   $ 133,657
Research and development expense       1,085,287 $ 270,545  
Collaboration loss sharing       2,130    
ADSs            
Equity Method Investment, Ownership Percentage     25.00%      
Equity Method Investment, Aggregate Cost     $ 150,000      
Per share price $ 27.65   $ 41.33      
Lock-up period     18 months      
Discount for lack of marketability $ 4,900          
Fair value of shares 95,500 85,600   $ 85,600    
Long term investments 95,500          
Research and development expense $ 54,500          
MorphoSys AG            
Upfront payment under license agreement   $ 750,000        
Equity Method Investment, Ownership Percentage   3.00%   3.00%    
Unrealized gain (loss) on long term investments       $ (9,900)    
Research and development expense       $ 11,600    
Profit (loss) sharing ratio       50.00%    
Collaboration loss sharing       $ 2,100    
MorphoSys AG | Accrued and other liabilities            
Accrued and other liabilities   $ 13,100   $ 13,100    
MorphoSys AG | Development and Regulatory Milestones | Maximum            
Additional milestone payments under the license agreement     $ 740,000      
MorphoSys AG | Commercialization Milestones | Maximum            
Additional milestone payments under the license agreement     $ 315,000      
MorphoSys AG | MorphoSys AG            
Funding of future development costs (as a percent)     45.00%      
MorphoSys AG | Incyte            
Funding of future development costs (as a percent)     55.00% 55.00%    
[1] The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.